Abstract
7047Background: Early prediction of response in acute myeloid leukemia (AML) patients undergoing cytotoxic chemotherapy may have clinical utility. Currently, measurable residual disease (MRD) testi...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
